BIO
Bio-Rad Laboratories, Inc.
BIO's fundamentals are mixed: it turned 13% of its revenue into free cash flow, but its operating margin went from 8.8% to −2.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BIO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Strong |
BIO's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4.5x | $169 | -54% |
| Fair | 7.4x | $280 | -24% |
| Current | 9.8x | $370 | — |
| Expensive | 31x | $1,157 | +212% |
| Forward | 35x | $370 | — |
Historical ranges are pointers, not guarantees.
BIO's PE is 9.8x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BIO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BIO's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.69 | -72% |
| Q3 2026 | $37.91 | +$62.22 |
| Q2 2026 | $8.19 | -30% |
| Q1 2026 | $6.01 | +$82.21 |
| Q4 2025 | $27.85 | +$92.89 |
| Q3 2025 | -$24.31 | +$3.02 |
| Q2 2025 | $11.73 | +$58.76 |
| Q1 2025 | -$76.20 | -$65.84 |
| Q4 2024 | -$65.04 | -$43.55 |
BIO has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $656.4M | +0.5% |
| Q2 2026 | $651M | -0.1% |
| Q1 2026 | $592.1M | +1.1% |
| Q4 2025 | $693.2M | +3.9% |
| Q3 2025 | $653M | +0.5% |
| Q2 2025 | $651.6M | +2.1% |
| Q1 2025 | $585.4M | -4.2% |
| Q4 2024 | $667.5M | -2% |
BIO's revenue fell from its 2020 peak and has held roughly level since: $656M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.6% | -18 points |
| Q2 2026 | 11% | -0.7 points |
| Q1 2026 | 5.8% | +1.7 points |
| Q4 2025 | -17% | -26 points |
| Q3 2025 | 10% | +0.1 points |
| Q2 2025 | 12% | -4.1 points |
| Q1 2025 | 4% | -3.3 points |
| Q4 2024 | 8.7% | -5.3 points |
BIO's operating margin was −7.6% last quarter, down 18 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BIO on profitability, with a higher operating margin.
BIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $65.2M | -27% |
| Q2 2026 | $66.7M | -5.8% |
| Q1 2026 | $78.1M | -18% |
| Q4 2025 | $119.1M | +47% |
| Q3 2025 | $89.2M | -28% |
| Q2 2025 | $70.8M | +28% |
| Q1 2025 | $95.5M | +222% |
| Q4 2024 | $81.2M | +109% |
BIO still generates free cash flow, though less than at its 2020 peak: $329M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BIO on cash flow, with more consistent year-over-year improvement.
BIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +131K shares |
| 1 year | +0.1% | +22K shares |
| 3 years | -7.8% | -2.3M shares |
| 5 years | -11% | -3.3M shares |
| Available history | -11% | -3.2M shares |
BIO has 27M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $31.5M |
| Q1 2026 | $47.8M |
| Q4 2025 | — |
| Q3 2025 | $53.4M |
| Q2 2025 | $140.2M |
| Q1 2025 | $101.9M |
| Q4 2024 | $14,000 |
BIO spent $79M buying back its own shares over the past year, down 73% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -1.6x | Net Cash |
| Q4 2019 | -1.8x | Net Cash |
BIO has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 66.5 | Neutral |
BIO's weekly RSI is 59 (neutral) and its Stochastic is 67 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BIO PE vs Healthcare Sector
| Metric | BIO | Sector median | Relative |
|---|---|---|---|
| PE | 9.8x | 26x | 62% below |
| PE % | 67 | 29 | 38 pts above |
BIO is trading at 9.8x earnings, a 62% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $370.5 | 0% below |
| 20 week MA | $355.5 | 4.2% above |
| 50 week MA | $314.3 | 18% above |
| 100 week MA | $297.5 | 25% above |
| 200 week MA | $326.1 | 14% above |
BIO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $368.4 | $575.1 | +56% |
| 2021 | $575.1 | $746.3 | +30% |
| 2022 | $746.3 | $412.7 | -45% |
| 2023 | $412.7 | $322.9 | -22% |
| 2024 | $322.9 | $330.9 | +2.5% |
| 2025 | $330.9 | $303.9 | -8.2% |
| 2026 YTD | $303.9 | $370.5 | +22% |
BIO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.